Sanofi Accelerates Beyfortus Shipments for Upcoming RSV Season

The latest announcement is out from Sanofi ( (SNY) ).

In June 2025, Sanofi announced the acceleration of global shipments of Beyfortus (nirsevimab) to prepare healthcare providers for the 2025-2026 RSV season. This initiative, in collaboration with AstraZeneca, aims to ensure broad availability of the only RSV protection designed for all infants. Since its launch in 2023, Sanofi has significantly increased production capacity and manufacturing sites to meet growing demand. The company has already matched last year’s supply and continues production to cover every infant, reflecting its commitment to timely access. Beyfortus, with its extended protection duration, is set to immunize millions more infants worldwide, offering significant public health benefits.

The most recent analyst rating on (SNY) stock is a Hold with a $67.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.

Spark’s Take on SNY Stock

According to Spark, TipRanks’ AI Analyst, SNY is a Neutral.

Sanofi’s overall stock score reflects strong financial performance and positive earnings call highlights, including robust sales growth and strategic initiatives. However, technical analysis indicates bearish momentum, and cash flow weaknesses along with market uncertainties slightly temper the outlook.

To see Spark’s full report on SNY stock, click here.

More about Sanofi

Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives through innovative medicines and vaccines. The company focuses on addressing urgent healthcare, environmental, and societal challenges, leveraging its deep understanding of the immune system to treat and protect millions globally. Sanofi is listed on EURONEXT and NASDAQ.

Average Trading Volume: 2,684,367

Technical Sentiment Signal: Buy

Current Market Cap: $121B

See more insights into SNY stock on TipRanks’ Stock Analysis page.